Document is current
Any future updates will be listed below
-
Authors
Shklovskaya, Elena
Pedersen, Bernadette
Lim, Su Yin
Irvine, Mal
Brown, Jesse R.
Pinho, Andreia V.
Shivalingam, Brindha
Menzies, Alexander M.
Satgunaseelan, Laveniya
Alexander, Kimberley L.
Di Ieva, Antonio
Long, Georgina V.
Chan, Wei Yen
Rizos, Helen
-
Funding
Funding for this research was provided by:
Australian Cancer Research Foundation
Macquarie University Research Acceleration Scheme
Cure Brain Cancer Foundation
Tour De Cure
- License Information
-
More Information
Article History
Received: 12 August 2025
Accepted: 22 May 2026
First Online: 30 May 2026
Competing interests
: G.V.L. is a consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L, IO Biotech, Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Regeneron. A.M.M. is a consultant advisor for BMS, MSD, Novartis, Pierre-Fabre, Roche and QBiotics. All other authors declare no competing interests.
